Ann: June 2021 Quarterly Report and Appendix 4C, page-4

First 4 Last

Share
Profile

Follow
justicej

181 Posts.

21

30/07/21

09:54

Post #: 54893408
Share

Originally posted by Logic[Al]: ↑

Next 6-9 months are going to prove if management are full of sh1t or not
Acquiring the most popular VET provider would give it the most cross selling exposure. Focus on that, get it done ASAP and capitalise on the cross sells.

This entire year can’t be viewed as positive from a $ viewpoint seeing as we’re in the same place as last year but only there due to acquisitions! Cosamp would have offset the reseller revenue loss.

The reseller loss was touted as insignificant to the bottom line due to low margins in the last announcement, so not sure why they didn’t mention that this time.

We haven’t had cosamp and Ripponlea onboard for long, so this year is the first year we’ll be able to see the cross sell come into play if at all.

With 6.3m in the bank, +ve EBITDA, expected $9m+ revenue FY22, in a defensive market (to abate market instability fears), a 38.5m market cap, there’s certainly enough keep me around but patience and credibility are toward the end of their tether for me.

I think it’s a hold because I believe that economies of scale are set. I think that predominately any additional revenue put on now will mostly hit the bottom line. That’s the only consideration that can make this year a positive, is if they set the fundamentals to scale now.

Big FY22 ahead

Expand

What he said!

Hoped-for spike in VET hasn't materialised.

8000 in April 2020 became 9000 in June 2020. This time 12000 in April 2021 has become "over 14000" in June, but with 2000 coming from the recent acquisition.

Additionally, bugger all bump in annual revenue from March to year end now.

All said, nothing really has changed from April. Bottom drawer for 6 months now and see if all these opportunities now on the table can be converted.

RCL Price at posting: 32.5¢ Sentiment: Hold Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

RCE

Recce's R327 found effective against E.coli during clinical trial

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

There are more pages in this discussion • 11 more messages in this thread...

First 4 Last

Add RCL (ASX) to my watchlist

(20min delay)
Last 8.3¢		Change 0.002(2.47%)		Mkt cap ! $12.13M

Open	High	Low	Value	Volume
8.1¢	8.5¢	8.1¢	$17.31K	206.5K

Buyers (Bids)

No.	Vol.	Price($)
1	54500	8.3¢

Sellers (Offers)

Price($)	Vol.	No.
8.6¢	5973	1

View Market Depth

No.	Vol.	Price($)
1	54500	0.083
1	48844	0.081
1	12000	0.080
1	12625	0.079
1	130000	0.078

Price($)	Vol.	No.
0.091	30000	1
0.095	400000	2
0.099	989	1
0.100	40000	1
0.105	25000	1

Last trade - 16.10pm 28/06/2024 (20 minute delay)

RCL (ASX) Chart

Ann: June 2021 Quarterly Report and Appendix 4C, page-4

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Recce's R327 found effective against E.coli during clinical trial

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: June 2021 Quarterly Report and Appendix 4C, page-4

Top Stories

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Recce's R327 found effective against E.coli during clinical trial

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News